Michael G. Kauffman's most recent trade in Kezar Life Sciences Inc was a trade of 5,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 18, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kezar Life Sciences Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| FibroGen Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2025 | 120,000 | 120,000 | - | - | Stock Option (Right to Buy) | |
| FibroGen Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2025 | 70,000 | 70,000 | - | - | Stock Option (Right to Buy) | |
| Verastem Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2025 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | |
| Verastem Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2025 | 8,333 | 17,216 (0%) | 0% | 0 | Common Stock | |
| Adicet Bio Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Aug 2024 | 37,000 | 37,000 | - | - | Stock Option (Right to Buy) | |
| Adicet Bio Inc | Michael Glen Kauffman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Aug 2024 | 37,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Adicet Bio Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Aug 2024 | 26,400 | 26,400 | - | - | Stock Option (Right to Buy) | |
| Adicet Bio Inc | Michael Glen Kauffman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Aug 2024 | 26,400 | 0 | - | - | Stock Option (Right to Buy) | |
| Adicet Bio Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Aug 2024 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Adicet Bio Inc | Michael Glen Kauffman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Aug 2024 | 18,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Verastem Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | |
| Verastem Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 8,333 | 8,883 (0%) | 0% | 0 | Common Stock | |
| Adicet Bio Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 26,400 | 26,400 | - | - | Stock Option (Right to Buy) | |
| Adicet Bio Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 5,900 | 11,800 | - | 0 | Common Stock | |
| Adicet Bio Inc | Michael Glen Kauffman | Director | Sale of securities on an exchange or to another person at price $ 1.43 per share. | 05 Jun 2024 | 5,900 | 5,900 | - | 1.4 | 8,437 | Common Stock |
| Verastem Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2024 | 16,078 | 16,078 | - | - | Stock Option (right to buy) | |
| Verastem Inc | Michael Glen Kauffman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Mar 2024 | 2,083 | 0 | - | - | Stock Option (right to buy) | |
| Verastem Inc | Michael Glen Kauffman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Mar 2024 | 2,083 | 0 | - | - | Stock Option (right to buy) | |
| Verastem Inc | Michael Glen Kauffman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Mar 2024 | 2,083 | 0 | - | - | Stock Option (right to buy) | |
| Verastem Inc | Michael Glen Kauffman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Mar 2024 | 2,083 | 0 | - | - | Stock Option (right to buy) | |
| Verastem Inc | Michael Glen Kauffman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Mar 2024 | 2,083 | 0 | - | - | Stock Option (right to buy) | |
| Verastem Inc | Michael Glen Kauffman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Mar 2024 | 2,083 | 0 | - | - | Stock Option (right to buy) | |
| Verastem Inc | Michael Glen Kauffman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Mar 2024 | 2,083 | 0 | - | - | Stock Option (right to buy) | |
| Verastem Inc | Michael Glen Kauffman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Mar 2024 | 1,497 | 0 | - | - | Stock Option (right to buy) | |
| Adicet Bio Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 37,000 | 37,000 | - | - | Stock Option (Right to Buy) | |
| Adicet Bio Inc | Michael Glen Kauffman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 37,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Adicet Bio Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 26,400 | 26,400 | - | - | Stock Option (Right to Buy) | |
| Adicet Bio Inc | Michael Glen Kauffman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 26,400 | 0 | - | - | Stock Option (Right to Buy) | |
| Adicet Bio Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Adicet Bio Inc | Michael Glen Kauffman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 14 Aug 2023 | 18,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Michael Glen Kauffman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 26,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Michael Glen Kauffman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 26,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Michael Glen Kauffman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 8,896 | 0 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 8,896 | 8,896 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Michael Glen Kauffman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 8,896 | 0 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 8,896 | 8,896 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Adicet Bio Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 26,400 | 26,400 | - | - | Stock Option (Right to Buy) | |
| Adicet Bio Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 5,900 | 5,900 | - | 0 | Common Stock | |
| Verastem Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2023 | 62,500 | 62,500 | - | - | Stock Option (right to buy) | |
| Kezar Life Sciences Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 26,000 | 26,000 | - | - | Stock Option (right to buy) | |
| Adicet Bio Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Verastem Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2022 | 62,500 | 62,500 | - | - | Stock Option (right to buy) | |
| Karyopharm Therapeutics Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 27,000 | 27,000 | - | - | Stock Option (right to buy) | |
| Karyopharm Therapeutics Inc | Michael Glen Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 21,000 | 719,983 (1%) | 0% | 0 | Common Stock | |
| Karyopharm Therapeutics Inc | Michael Glen Kauffman | Director | Sale of securities on an exchange or to another person at price $ 10.24 per share. | 28 Feb 2022 | 6,226 | 898,131 (1%) | 0% | 10.2 | 63,739 | Common Stock |
| Karyopharm Therapeutics Inc | Michael Glen Kauffman | Director | Sale of securities on an exchange or to another person at price $ 10.24 per share. | 28 Feb 2022 | 6,226 | 713,757 (1%) | 0% | 10.2 | 63,739 | Common Stock |
| Karyopharm Therapeutics Inc | Michael Glen Kauffman | Director | Sale of securities on an exchange or to another person at price $ 12.12 per share. | 17 Feb 2022 | 9,088 | 904,357 (1%) | 0% | 12.1 | 110,177 | Common Stock |
| Karyopharm Therapeutics Inc | Michael Glen Kauffman | Director | Sale of securities on an exchange or to another person at price $ 12.12 per share. | 17 Feb 2022 | 9,079 | 698,983 (1%) | 0% | 12.1 | 110,068 | Common Stock |
| Karyopharm Therapeutics Inc | Michael Glen Kauffman | Director | Sale of securities on an exchange or to another person at price $ 9.86 per share. | 07 Feb 2022 | 6,764 | 708,062 (1%) | 0% | 9.9 | 66,707 | Common Stock |
| Karyopharm Therapeutics Inc | Michael Glen Kauffman | Director | Sale of securities on an exchange or to another person at price $ 9.86 per share. | 07 Feb 2022 | 6,707 | 913,445 (1%) | 0% | 9.9 | 66,144 | Common Stock |
| Kezar Life Sciences Inc | Michael Glen Kauffman | Director | Sale of securities on an exchange or to another person at price $ 16.45 per share. | 03 Jan 2022 | 5,000 | 63,690 (0%) | 0% | 16.5 | 82,250 | Common Stock |
| Kezar Life Sciences Inc | Michael Glen Kauffman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2022 | 5,000 | 3,896 | - | - | Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | Michael Glen Kauffman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.91 per share. | 03 Jan 2022 | 5,000 | 68,690 (0%) | 0% | 5.9 | 29,550 | Common Stock |
| Adicet Bio Inc | Michael G. Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Nov 2021 | 37,000 | 37,000 | - | - | Stock Option (right to Buy) | |
| Kezar Life Sciences Inc | Michael G. Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2021 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| Verastem Inc | Michael G. Kauffman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2021 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Karyopharm Therapeutics Inc | Michael G. Kauffman | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 12.39 per share. | 18 Mar 2021 | 4,000 | 714,826 (1%) | 0% | 12.4 | 49,553 | Common Stock |
| Karyopharm Therapeutics Inc | Michael G. Kauffman | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 153,500 | 153,500 | - | - | Stock Option (right to buy) | |
| Karyopharm Therapeutics Inc | Michael G. Kauffman | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 153,500 | 153,500 | - | - | Stock Option (right to buy) | |
| Karyopharm Therapeutics Inc | Michael G. Kauffman | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 57,200 | 718,826 (1%) | 0% | 0 | Common Stock | |
| Karyopharm Therapeutics Inc | Michael G. Kauffman | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 57,200 | 920,152 (1%) | 0% | 0 | Common Stock | |
| Karyopharm Therapeutics Inc | Michael G. Kauffman | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 14.83 per share. | 18 Feb 2021 | 9,495 | 575,126 (0%) | 0% | 14.8 | 140,822 | Common Stock |
| Karyopharm Therapeutics Inc | Michael G. Kauffman | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 14.83 per share. | 18 Feb 2021 | 9,495 | 776,452 (1%) | 0% | 14.8 | 140,822 | Common Stock |
| Karyopharm Therapeutics Inc | Michael G. Kauffman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2021 | 21,800 | 43,600 | - | - | Restricted Stock Units | |
| Karyopharm Therapeutics Inc | Michael G. Kauffman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2021 | 21,800 | 43,600 | - | - | Restricted Stock Units | |
| Karyopharm Therapeutics Inc | Michael G. Kauffman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2021 | 21,800 | 785,947 (1%) | 0% | - | Common Stock | |
| Karyopharm Therapeutics Inc | Michael G. Kauffman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2021 | 21,800 | 584,621 (0%) | 0% | - | Common Stock | |
| Karyopharm Therapeutics Inc | Michael G. Kauffman | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 15.52 per share. | 11 Feb 2021 | 6,642 | 764,147 (1%) | 0% | 15.5 | 103,077 | Common Stock |
| Karyopharm Therapeutics Inc | Michael G. Kauffman | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 15.52 per share. | 11 Feb 2021 | 6,601 | 562,821 (0%) | 0% | 15.5 | 102,441 | Common Stock |
| Karyopharm Therapeutics Inc | Michael G. Kauffman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2021 | 14,300 | 770,789 (1%) | 0% | - | Common Stock | |
| Karyopharm Therapeutics Inc | Michael G. Kauffman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2021 | 14,300 | 42,900 | - | - | Restricted Stock Units | |
| Karyopharm Therapeutics Inc | Michael G. Kauffman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2021 | 14,300 | 42,900 | - | - | Restricted Stock Units | |
| Karyopharm Therapeutics Inc | Michael G. Kauffman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2021 | 14,300 | 569,422 (0%) | 0% | - | Common Stock | |
| Karyopharm Therapeutics Inc | Michael G. Kauffman | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 14.89 per share. | 12 Oct 2020 | 7,500 | 756,489 (1%) | 0% | 14.9 | 111,683 | Common Stock |
| Karyopharm Therapeutics Inc | Michael G. Kauffman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.03 per share. | 12 Oct 2020 | 6,076 | 763,989 (1%) | 0% | 0.0 | 201 | Common Stock |
| Karyopharm Therapeutics Inc | Michael G. Kauffman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Oct 2020 | 6,076 | 0 | - | - | Stock Option (right to buy) | |
| Karyopharm Therapeutics Inc | Michael G. Kauffman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.03 per share. | 12 Oct 2020 | 1,424 | 757,913 (1%) | 0% | 0.0 | 47 | Common Stock |
| Karyopharm Therapeutics Inc | Michael G. Kauffman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Oct 2020 | 1,424 | 0 | - | - | Stock Option (right to buy) | |
| Karyopharm Therapeutics Inc | Michael G. Kauffman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2020 | 1,477 | 6,076 | - | - | Stock Option (right to buy) | |
| Karyopharm Therapeutics Inc | Michael G. Kauffman | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 15.00 per share. | 17 Aug 2020 | 1,477 | 756,489 (1%) | 0% | 15 | 22,155 | Common Stock |
| Karyopharm Therapeutics Inc | Michael G. Kauffman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.03 per share. | 17 Aug 2020 | 1,477 | 757,966 (1%) | 0% | 0.0 | 49 | Common Stock |
| Karyopharm Therapeutics Inc | Michael G. Kauffman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.03 per share. | 15 Jul 2020 | 7,500 | 763,989 (1%) | 0% | 0.0 | 248 | Common Stock |
| Karyopharm Therapeutics Inc | Michael G. Kauffman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2020 | 7,500 | 1,424 | - | - | Stock Option (right to buy) | |
| Karyopharm Therapeutics Inc | Michael G. Kauffman | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 19.43 per share. | 15 Jul 2020 | 7,500 | 756,489 (1%) | 0% | 19.4 | 145,723 | Common Stock |